Gala GLP-1
Gala GLP-1 is a telehealth platform operated by AI Coaching Inc. that provides personalized, doctor-prescribed GLP-1 medications for weight loss. The company offers weekly injectable GLP-1 and GLP-1/GIP medications sourced from licensed compounding pharmacies, supported by a network of over 20,000 clinicians across all 50 states. Gala GLP-1 integrates an AI-powered app for medication management, dosage tracking, and lifestyle guidance to support sustainable weight loss. The platform facilitates telehealth consultations with licensed providers who review patient information and prescribe medications if medically appropriate. Gala GLP-1 operates on a subscription model starting at $200 per month and emphasizes continuous online support and personalized treatment plans. The company has documented over 25,000 success stories and provides a user-friendly app for managing treatment and appointments.
Gala GLP-1
Gala GLP-1 is a telehealth platform operated by AI Coaching Inc. that provides personalized, doctor-prescribed GLP-1 medications for weight loss. The company offers weekly injectable GLP-1 and GLP-1/GIP medications sourced from licensed compounding pharmacies, supported by a network of over 20,000 clinicians across all 50 states. Gala GLP-1 integrates an AI-powered app for medication management, dosage tracking, and lifestyle guidance to support sustainable weight loss. The platform facilitates telehealth consultations with licensed providers who review patient information and prescribe medications if medically appropriate. Gala GLP-1 operates on a subscription model starting at $200 per month and emphasizes continuous online support and personalized treatment plans. The company has documented over 25,000 success stories and provides a user-friendly app for managing treatment and appointments.
TL;DR
Product: AI-powered telehealth app for GLP-1 medication management
Business model: Subscription-based care starting at $200/month
Clinician network: Claims a network of over 20,000 clinicians across all 50 U.S. states
Funding: Pre-Seed round announced 2024-12-16; investor: Antler
Founders: Fede Buldin and Javi d'Erausquin
Documents over 25,000 success stories
Company Overview
Problem Domain
Weight-loss medication adherence and treatment management for patients using GLP-1 therapies
Founded
2023
Industry
Telehealth
Tech Stack
Funding Track Record
Amount not disclosed publicly
Investor Signal
“Backed by Antler (investor in Pre-Seed round announced 2024-12-16)”